July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Three loci associated with risk of advanced age-related macular degeneration (AMD) also influence anti-VEGF treatment response
Author Affiliations & Notes
  • William K Scott
    Hussman Institute for Human Genomics, University of Miami, Miami, Florida, United States
  • Omar García Rodríguez
    Hussman Institute for Human Genomics, University of Miami, Miami, Florida, United States
  • Patrice Whitehead-Gay
    Hussman Institute for Human Genomics, University of Miami, Miami, Florida, United States
  • Larry D. Adams
    Hussman Institute for Human Genomics, University of Miami, Miami, Florida, United States
  • Jacob K. Welch
    Hussman Institute for Human Genomics, University of Miami, Miami, Florida, United States
  • Renee Laux
    Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, United States
  • Milam A Brantley
    Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Jaclyn L. Kovach
    Bascom Palmer Eye Institute, University of Miami, Naples, Florida, United States
  • Stephen G Schwartz
    Bascom Palmer Eye Institute, University of Miami, Naples, Florida, United States
  • Anita Agarwal
    Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States
    West Coast Retina, San Francisco, California, United States
  • Jonathan L Haines
    Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, United States
  • Margaret A Pericak-Vance
    Hussman Institute for Human Genomics, University of Miami, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   William Scott, None; Omar García Rodríguez, None; Patrice Whitehead-Gay, None; Larry Adams, None; Jacob Welch, None; Renee Laux, None; Milam Brantley, None; Jaclyn Kovach, None; Stephen Schwartz, Alimera (C), Welch Allyn (C); Anita Agarwal, None; Jonathan Haines, None; Margaret Pericak-Vance, None
  • Footnotes
    Support  NIH/NEI R01EY012118
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2968. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      William K Scott, Omar García Rodríguez, Patrice Whitehead-Gay, Larry D. Adams, Jacob K. Welch, Renee Laux, Milam A Brantley, Jaclyn L. Kovach, Stephen G Schwartz, Anita Agarwal, Jonathan L Haines, Margaret A Pericak-Vance; Three loci associated with risk of advanced age-related macular degeneration (AMD) also influence anti-VEGF treatment response. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2968.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Response to anti-vascular endothelial growth factor (anti-VEGF) treatment for choroidal neovascularization (CNV) is variable. Fritsche et al. (2016) demonstrated that 52 single nucleotide polymorphisms (SNPs) in 34 loci account for 50% of the variation in the risk of developing AMD. Most genetic studies of treatment response have examined the association of these known genetic risk factors on treatment response, with few replicated results. We tested these AMD SNPs to clarify the inconsistent results.

Methods : We examined the association between 15,161 SNPs in these 34 loci and one-year change in visual acuity (VA) in 90 non-Hispanic white individuals with CNV (107 eyes) treated monthly for the first three months and as needed afterward. Samples were genotyped using the Illumina HumanCoreExome-24 and imputed against the 1000 Genomes Project Phase I reference panel. Association of one-year change in VA (measured as the change in logMAR) with SNP dosage was analyzed using linear mixed models, adjusting for age, sex, treatment, correlation of paired eyes, and population substructure (the top 3 principal components from EIGENSTRAT analysis).

Results : There were six variants in three AMD risk loci significantly associated with treatment response when correcting for the 34 loci tested (α=1.5 x 10-3). Each C allele at rs1951409 (p=9.62 x 10-4) and each A allele at rs199555630 (p=6.73 x 10-4) in RAD51B (pairwise linkage disequilibrium r2=0.28) were associated with worse VA one year after anti-VEGF treatment. Each T allele at rs117086110 (p=5.21 x 10-5) and each A allele at rs76904544 (p=6.00 x 10-5) in RAD51B (r2=0.94) were associated with improved VA. There was no linkage disequilibrium between the positively and negatively associated SNPs in RAD51B. Two other variants: rs2233739 (p=3.51 x 10-4) in LIPC and rs12519450 in PRLR/SPEF2 (p=1.28 x 10-3) were associated with improved VA.

Conclusions : Previous studies have not associated these six variants with anti-VEGF treatment response in CNV. RAD51B is involved in DNA repair and is associated with several cancers which may also be treated with anti-VEGF therapy. These findings could allow identifying individuals at risk of poorer treatment responses and particular genetic profile, which it could be used to prioritize for new treatments or altered therapeutic regimens.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×